Antengene

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene has established a pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets, four early-stage clinical assets. In addition, leveraging R&D capabilities, Antengene are internally developing six pre-clinical stage assets, which focus on novel targets or MoAs and hence have potential to address significant unmet medical needs. More importantly, these assets target the key oncogenic pathways and are highly synergistic to our pipeline assets.